SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2
- PMID: 20371709
- DOI: 10.1158/1535-7163.MCT-09-0971
SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2
Abstract
SIRT proteins play an important role in the survival and drug resistance of tumor cells, especially during chemotherapy. In this study, we investigated the potency, specificity, and cellular targets of three SIRT inhibitors, Sirtinol, Salermide, and EX527. Cell proliferative and cell cycle analyses showed that Sirtinol and Salermide, but not EX527, were effective in inducing cell death at concentrations of 50 micromol/L or over in MCF-7 cells. Instead, EX527 caused cell cycle arrest at G(1) at comparable concentrations. In vitro SIRT assays using a p53 peptide substrate showed that all three compounds are potent SIRT1/2 inhibitors, with EX527 having the highest inhibitory activity for SIRT1. Computational docking analysis showed that Sirtinol and Salermide have high degrees of selectivity for SIRT1/2, whereas EX527 has high specificity for SIRT1 but not SIRT2. Consistently, Sirtinol and Salermide, but not EX527, treatment resulted in the in vivo acetylation of the SIRT1/2 target p53 and SIRT2 target tubulin in MCF-7 cells, suggesting that EX527 is ineffective in inhibiting SIRT2 and that p53 mediates the cytotoxic function of Sirtinol and Salermide. Studies using breast carcinoma cell lines and p53-deficient mouse fibroblasts confirmed that p53 is essential for the Sirtinol and Salermide-induced apoptosis. Further, we showed using small interfering RNA that silencing both SIRTs, but not SIRT1 and SIRT2 individually, can induce cell death in MCF-7 cells. Together, our results identify the specificity and cellular targets of these novel inhibitors and suggest that SIRT inhibitors require combined targeting of both SIRT1 and SIRT2 to induce p53 acetylation and cell death. Mol Cancer Ther; 9(4); 844-55. (c)2010 AACR.
Similar articles
-
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.Oncogene. 2009 Feb 12;28(6):781-91. doi: 10.1038/onc.2008.436. Epub 2008 Dec 8. Oncogene. 2009. PMID: 19060927
-
Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells.Int J Oncol. 2012 Sep;41(3):1101-9. doi: 10.3892/ijo.2012.1534. Epub 2012 Jun 26. Int J Oncol. 2012. PMID: 22751989
-
Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).Cancer Biol Ther. 2016;17(3):300-9. doi: 10.1080/15384047.2016.1139246. Epub 2016 Jan 21. Cancer Biol Ther. 2016. PMID: 26794150 Free PMC article.
-
Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.Curr Med Chem. 2012;19(34):5871-84. doi: 10.2174/092986712804143303. Curr Med Chem. 2012. PMID: 22998567 Review.
-
Molecular and cellular regulatory roles of sirtuin protein.Crit Rev Food Sci Nutr. 2023;63(29):9895-9913. doi: 10.1080/10408398.2022.2070722. Epub 2022 May 5. Crit Rev Food Sci Nutr. 2023. PMID: 35510883 Review.
Cited by
-
Virtual Screening in the Identification of Sirtuins' Activity Modulators.Molecules. 2022 Sep 1;27(17):5641. doi: 10.3390/molecules27175641. Molecules. 2022. PMID: 36080416 Free PMC article. Review.
-
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.EMBO Mol Med. 2012 Apr;4(4):298-312. doi: 10.1002/emmm.201100211. Epub 2012 Feb 13. EMBO Mol Med. 2012. PMID: 22331558 Free PMC article.
-
BZD9L1 sirtuin inhibitor as a potential adjuvant for sensitization of colorectal cancer cells to 5-fluorouracil.Ther Adv Med Oncol. 2019 Sep 27;11:1758835919878977. doi: 10.1177/1758835919878977. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31632470 Free PMC article.
-
SIRT1: A promising therapeutic target for chronic pain.CNS Neurosci Ther. 2022 Jun;28(6):818-828. doi: 10.1111/cns.13838. Epub 2022 Apr 9. CNS Neurosci Ther. 2022. PMID: 35396903 Free PMC article. Review.
-
Controversial Impact of Sirtuins in Chronic Non-Transmissible Diseases and Rehabilitation Medicine.Int J Mol Sci. 2018 Oct 9;19(10):3080. doi: 10.3390/ijms19103080. Int J Mol Sci. 2018. PMID: 30304806 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous